LivaNova (NASDAQ:LIVN) Raised to Hold at Freedom Capital

LivaNova (NASDAQ:LIVN) was upgraded by investment analysts at Freedom Capital to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

Several other equities research analysts also recently weighed in on LIVN. Barclays increased their price target on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Mizuho upped their price objective on shares of LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. KeyCorp raised their target price on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Monday, June 22nd. Weiss Ratings raised shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Finally, Robert W. Baird dropped their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, LivaNova currently has an average rating of “Moderate Buy” and an average price target of $80.75.

LivaNova Stock Performance

NASDAQ LIVN opened at $83.62 on Tuesday. The firm has a market cap of $4.59 billion, a P/E ratio of 42.88 and a beta of 0.86. LivaNova has a 52-week low of $41.01 and a 52-week high of $83.98. The business’s 50-day moving average price is $73.58 and its 200 day moving average price is $67.51. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The firm had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. During the same period in the prior year, the business earned $0.88 EPS. The firm’s revenue was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, equities research analysts expect that LivaNova will post 3.73 earnings per share for the current year.

Insider Transactions at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the sale, the director directly owned 7,228 shares in the company, valued at approximately $547,521. The trade was a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.35% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Hantz Financial Services Inc. boosted its position in shares of LivaNova by 159.9% in the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after buying an additional 267 shares in the last quarter. State of Wyoming purchased a new position in LivaNova during the 2nd quarter valued at about $31,000. EverSource Wealth Advisors LLC raised its position in LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after acquiring an additional 639 shares during the last quarter. Quarry LP acquired a new position in LivaNova during the third quarter worth about $36,000. Finally, Covestor Ltd lifted its holdings in shares of LivaNova by 108.6% in the fourth quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after purchasing an additional 392 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.